RxDoctor Payments Data

Miriam Staub, MD

Child & Adolescent Psychiatry · Riverside, CANPI 1043593569

Payments from drug & device makers

$1,156in general payments, 2019–2025

Across 47 payments — averaging $24.60 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Sunovion Pharmaceuticals Inc.$257
  • AbbVie$232
  • Otsuka America Pharmaceutical, Inc.$172
  • Teva Pharmaceuticals USA, Inc.$142
  • Alkermes, Inc.$109
  • Neurocrine Biosciences, Inc.$69
  • plus $176 from 4 others

What the payments were for

  • Food & beverage$1,156100%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$1,156 in reported general payments places this provider in the 80th percentile of 434 child & adolescent psychiatry providers in California.

See all child & adolescent psychiatry providers in California

Medicare billing

Part B allowed, 2024
$10,919
Medicare patients
39
Services billed
145

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
RexultiBrexpiprazole34$52,922
Invega SustennaPaliperidone Palmitate13$51,707
Risperidone ErRisperidone Microspheres28$40,374
Abilify MaintenaAripiprazole14$38,494
Zyprexa RelprevvOlanzapine Pamoate21$18,195
Lurasidone Hcl79$17,663
TrintellixVortioxetine Hydrobromide28$15,155
VyvanseLisdexamfetamine Dimesylate20$11,562
Clozapine149$8,507
Aripiprazole82$8,387
Desvenlafaxine Succinate ErDesvenlafaxine Succinate101$6,315
Bupropion XlBupropion Hcl95$4,918
Quetiapine Fumarate133$4,503
Olanzapine94$3,882
Buprenorphine-NaloxoneBuprenorphine Hcl/Naloxone Hcl43$3,047

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
Otsuka America Pharmaceutical, Inc.Rexulti, Abilify Maintena$172$91,41648 claims
Johnson & JohnsonInvega Sustenna$68$51,70713 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 80th percentile of 434 child & adolescent psychiatry providers in California.

Other child & adolescent psychiatry in Riverside

See the full list for California

Where these figures come from

Is this you, or does something look wrong? →